EUVIMEDEUVIMED entdecken
Crossref

Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis

B L Heesterman iD, M Peters, D E Oprea-Lager, A J A T Braat, I G Schoots, C C Loeff, P J van Leeuwen, R C N van den Bergh, D A Palma, K K H Aben, W S C Eppinga

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07431-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von B L Heesterman und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands. b.heesterman@iknl.nl. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the effects of prostate-specific membrane antigen (PSMA) PET/CT use for primary staging on nationwide stage-specific prostate cancer (PCa) incidence rates and treatment patterns. METHODS: For this population-based cohort study, all men diagnosed with PCa in the Netherlands from 2010 to 2023 were identified in the Netherlands Cancer Registry. Year of diagnosis was used as proxy measure for PSMA PET/CT availability and use for primary staging. Overall and stage-specific European age-standardized incidence rates (ESR) and estimated annual percentages change (EAPC) were calculated. Among patients with ≥ 1 high-risk feature, logistic regression was performed to assess the association between year of diagnosis and detection of pelvic lymph node and/or distant metastases. Exploratory analyses were conducted to assess changes in treatment. RESULTS: From 2010 to 2023, the ESR of PCa declined slightly (EAPC=-0.2%, p = 0.64). Meanwhile, the ESR of pelvic node-positive only and distant metastatic PCa increased (EAPC = 4.6% [p < 0.001] and 4.1% [p < 0.001]). Patients with ≥ 1 high-risk feature were more often diagnosed with pelvic lymph node and/or distant metastases in the years with increasing (OR = 1.33) and widespread (OR = 1.65) access compared to the period with limited access to PSMA PET/CT for primary staging. Meanwhile, the proportion of patients that received systemic therapy increased from 38.7 to 42.0% (OR = 1.15). CONCLUSION: The implementation of PSMA PET/CT in clinical practice, appears to be associated with a substantial stage shift towards pelvic node-positive and distant metastatic PCa. Exploratory analyses also suggest more frequent treatment with palliative, rather than curative intent. Further research is needed to evaluate effects on clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedIncidenceMiddle AgedNetherlandsNeoplasm MetastasisAged, 80 and overNeoplasm StagingCohort Studies

Stichwörter der Autor:innen

IncidenceMetastasesPSMA PET/CTPrimary stagingProstate cancer

Substanzen

Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands. b.heesterman@iknl.nl.
  • Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Radiotherapiegroep, Deventer/Arnhem, the Netherlands.
  • Department of Radiology & Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

ORCID-Profile: B L Heesterman

Zitieren

APA

Heesterman, B. L., Peters, M., Oprea-Lager, D. E., Braat, A. J. A. T., Schoots, I. G., Loeff, C. C., van Leeuwen, P. J., van den Bergh, R. C. N., Palma, D. A., Aben, K. K. H., & Eppinga, W. S. C. (2025). Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07431-8

Vancouver

Heesterman BL, Peters M, Oprea-Lager DE, Braat AJAT, Schoots IG, Loeff CC, et al. Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07431-8

BibTeX
@article{Heesterman2025,
  author = {Heesterman, B L and Peters, M and Oprea-Lager, D E and Braat, A J A T and Schoots, I G and Loeff, C C and van Leeuwen, P J and van den Bergh, R C N and Palma, D A and Aben, K K H and Eppinga, W S C},
  title = {Increased incidence of primary metastatic prostate cancer in the era of PSMA PET/CT: a population-based analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07431-8}
}
Kostenlos starten →